What's New at TTBD
TTBD introduces automated outgoing MTAs
TTBD has developed an automated process for outgoing Material Transfer Agreements (MTAs). OHSU investigators, faculty, and lab staff are encouraged to submit material(s) to be posted to the TTBD website for transfer to other academic and research institutions for non-commercial research only. Individuals interested in these materials will use our eMTA automated process and all orders will be reviewed by the TTBD office prior to transfer. Register your Material(s).
Industry Collaboration Opportunities
Eli Lilly OIDD Program
The OIDD Program (previously known as the PD2 Initiative)
provides a means for screening potentially therapeutic compounds developed at academic research centers in Lilly's proprietary assay system. Lilly will screen compounds in a set of assay modules that include a primary phenotypic screening and secondary biochemical and cellular assays in the following areas:
- Cancer
- Bone Formation
- Endocrine/Diabetes
- Cardiovascular
- Neuroscience
- Rare and Neglected Diseases
